Idera Pharmaceuticals, Inc.:
Lead candidate Tilsotolimod (TLR 9 agonist) used in comb w Ipi in PD1 refractory melanoma pts. Enrolling addl pts in Ph 2 expansion and Phase 3 enrollment expected to complete Q4 2019. Combo of ipi and Tilsotolimod appears to activate immune response in pts who have exhausted all options, e.g. PD1/CPIs. Fast Track des for Tilsotolimod (Nov’17).
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by